This book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing. According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050. First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours. In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners.

Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics. - Provides accurate reviews from leading experts on the topic of pulmonary pharmacology - Each chapter of the volume provides consolidated graphical materials for ease of reading for the audience - Provides the latest insights and future perspectives on the drug discovery and development for respiratory diseases

Plant Bioactives as Natural Panacea Against Age-induced Diseases: Nutraceuticals and Functional Lead Compounds for Drug Development presents comprehensive information on the complications of aging and the bioactive phytochemicals that in specific herbal formulations, including beverages, can mitigate them. The book extensively describes the current information on the role of plant bioactive components in delaying or preventing the aging process and associated complications, while also covering different strategies and scientific evidence of possible synergistic effects of these studies, enabling the formulation of more effective natural drugs to intervene in aging and associated events. Chapters cover the broad areas of plant bioactive compounds in promoting healthy aging and longevity, including balancing glucose homeostasis, in cognitive impairments, age-related diseases, food trends and the anti-aging diet in Asia and other regions, as well as the social and economic impact of dietary patterns in aging interventions. Written by a team of global experts. - Describes plant bioactives for specific age disorders - Focuses on the discovery of new herbal origin drugs and potential druggable targets for the treatment of chronic diseases of world importance - Includes cutting-edge research information on cell senescence during aging and assesses the plant bioactive compounds

Winner of the 2023 PROSE award in Biomedicine and Neuroscience! Research in the field of senescence has boomed recently due to the gradual realization that senescent cells are associated with a significant number of diseases. The genetic or pharmacological elimination of senescent cells can cause widespread benefits and improves outcomes for most of those diseases. Cellular Senescence in Diseases presents an updated review of the role of cellular senescence in multiple pathologies. Focus is given to those diseases where the implication of senescence has been more extensively documented, such as (cancer, lung and liver diseases, diabetes, Neurodegenerative diseases and others). The Editors recruited a group of worldwide experts in each individual pathology to review the role of cellular senescence in each one of them, aiming at identifying potential therapeutic pathways. The first two chapters provide an overview of the cellular senescence principles. Next, the chapters are divided into specific diseases. Cancer, including premalignant lesions (OIS), Advanced disease (TIS), and Metastasis are covered. The following condition covered is Lund diseases, including IPF, COPD, and Pulmonary Hypertension. Next Liver Diseases are covered, including Fibrosis and Cirrhosis, and Fatty liver disease. Next there is coverage for Kidney implications, including fibrosis and transplantation. Vascular diseases are covered next including infarction and hear fibrosis, and atherosclerosis. Both diabetes types 1 and 2 are covered next. Following chapters cover Obesity, Sarcopenia, and Bone and Cartilage disorders, respectively. Neurodegenerative diseases are covered next, focusing on Alzheimer and Parkinson. The next chapter discusses accumulation of senescent cell in tissues during aging. The two final chapters cover current developments and conclusions. Cellular Senescence in Diseases is designed for researchers and clinicians with a focus on the cellular mechanisms of diseases. All chapters cover current experimental therapeutic approaches to eliminate or cancel the pathological effects of senescent cells. Pharmaceutical scientists may also benefit from the contents of the book in the exploration of novel therapeutic opportunities. - 2023 PROSE Awards - Winner: Category: Biomedicine and Neuroscience: Association of American Publishers - Provides a thorough introduction to Cellular Senescence - Covers all major pathologies for which cellular senescence has shown evidence of involvement - Focuses on possible therapeutic pathways - Edited and authored by worldwide experts

This book introduces charnolophagy (CP) as energy-driven, lysosomal-dependent mitochondrial inclusion-specific pleomorphic Charnoly body (CB) autophagy (ATG) involving free radical-induced Ca2+ dyshomeostasis, ΔΨ collapse, and ATP depletion in congenital diseases, pressure ulcers, metabolic diseases, hepatic diseases, diabetes, obesity, inflammatory diseases, musculoskeletal diseases, sarcopenia, cachexia, respiratory diseases, gastrointestinal diseases, hyperlipidemia, skin and hair diseases, pulmonary diseases, cardiovascular diseases, renal diseases, sepsis-induced multi-organ failure, reproductive diseases, inflammatory diseases, ophthalmic diseases, neurodegenerative diseases, drug addiction, aging, microbial (including COVID-19) infections, and belligerent malignancies implicated in early morbidity and mortality and disease-specific spatiotemporal, targeted, safe, and effective evidence-based personalized theranostic charnolopharmacotherapeutics to cure them. Basic DRESS and GELS principles, nanoparticles to cure chronic multidrug-resistant (MDR) diseases, antioxidants as free radical scavengers, CB antagonists, CP regulators, and CS stabilizers to curb CB molecular pathogenesis (CBMP) are described for better quality of life and longevity. Specific guidelines for environmental protection and preservation of zoological and botanical species at the verge of extinction, Triple "I" Hypothesis for mitochondrial quality control, and transcriptional regulation of CSexR and CSendoR to cure chronic diseases are presented. Novel CP index is introduced to evaluate MDR malignancies and other chronic diseases. WHO, CDC, FDA, NIH, policy planners, cosmetologists, trichologists, players, athletes, dancers, wrestlers, equestrians, young women, aging population, toxicologists, environmental protectionists, pharmaceutical industry, biomedical scientists, researchers, medical students, physicians, nurses, paramedical professionals, and global audience will be interested in this interesting book to prevent pandemics and raise healthcare awareness.

What Is Senolytic There is a family of tiny compounds known as senolytics that are now the subject of fundamental study to establish whether or not they may selectively trigger cell death in senescent cells and enhance human health. This study aims to find or create treatments that may postpone the onset of age-related disorders, prevent them, relieve their symptoms, or even reverse their effects. The term "senostatic," which meaning to inhibit senescence, is one that is associated with this idea. How You Will Benefit (I) Insights, and validations about the following topics: Chapter 1: Senolytic Chapter 2: Life extension Chapter 3: Dasatinib Chapter 4: p16 Chapter 5: CGK733 fraud Chapter 6: Bcl-xL Chapter 7: Chromatin remodeling Chapter 8: Telomerase reverse transcriptase Chapter 9: ID1 Chapter 10: Cellular senescence Chapter 11: Fisetin Chapter 12: NKG2D Chapter 13: Human umbilical vein endothelial cell Chapter 14: Genetics of aging Chapter 15: Navitoclax Chapter 16: Senotherapy Chapter 17: ABT-737 Chapter 18: Senescence-associated secretory phenotype Chapter 19: Hallmarks of aging Chapter 20: Timeline of senescence research Chapter 21: Laura Niedernhofer (II) Answering the public top questions about senolytic. (III) Real world examples for the usage of senolytic in many fields. (IV) 17 appendices to explain, briefly, 266 emerging technologies in each industry to have 360-degree full understanding of senolytic' technologies. Who This Book Is For Professionals, undergraduate and graduate students, enthusiasts, hobbyists, and those who want to go beyond basic knowledge or information for any kind of senolytic.

This handbook focuses on different aspects of anti-aging and both preventive and regenerative medicine. It includes analysis of the paradigm of ageing and concepts of anti-aging medicine. Standards and technologies are highlighted in over twenty chapters all authored by international experts in regenerative medicine. Topics covered include: • Ageing, aging, and anti-aging: A Decalogue for anti-aging medicine • Lessons from Sicilian centenarians for anti-aging medicine • Molecular biomarkers and genetic aspects of aging • Future of peptides in clinical practice • Mitochondrial approaches in anti-aging medicine and in SARS-CoV2 infection • Tissue-specific autoantibodies in preventive medicine • Chronic stress as a psycho-neuro-immunological dysfunction • Gut-associated immune system and its health implications • Regenerative medicine with platelet-rich-plasma • Alzheimer’s disease: Preventive and anti-aging neurology • Autistic spectrum disorder and mitochondrial medicine • Integrative hormonal approach in anti-aging medicine • Preventive cardiology and phlebology • Aesthetic and anti-aging medicine • Preventive ophthalmology • Preventive oncology • Nutrition in healthy aging • Physical activity and fitness paradigms for anti-aging and longevity Recommended reading for clinicians working in anti-aging medicine as well as ageing people. The authors hope it will set a new “standard of anti-aging medicine” and as a tool in planning for the inevitable challenges we all will face caring for ageing patients and creating preventive-health programs.

This book presents studies of the main conditions that affect health and well-being of old people. Considering the present scenario of COVID-19, the effects of this viral infection on individuals older than 65 years are also discussed. The content enables professionals of health and government for the present and future actions in this important area. Readers go through the changes occurring in organs and tissues that can interfere with susceptibility to infections, low response to vaccines, cancer, and loss of cognition during the aging process. A discussion of the central role played by the immune system in the age-related diseases and how the immunity can be impaired during the ageing process is presented. Possibilities to circumvent these conditions via healthy habits in diet, physical exercise, and new pharmacological interventions are part of the content. This book discusses how human healthy longevity is dependent, at least in part, of a functional immune system. Chapters were written for researchers in the field of aging and is especially suited for those interested in the study of immunosenescence and inflammaging affecting the health of old individuals.